Biochemical Befense - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511242683

Publication Date:

November 6, 2024

Pages:

129

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

The global market for Biochemical Befense was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Biochemical Befense was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Biochemical Befense was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Biochemical Befense was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Biochemical Befense include Emergent Biosolutions, Hytest, GSK, Sanofi, PharmAthene, Bavarian Nordic, SIGA Technologies, Arbutus Biopharma and DynPort Vaccine, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biochemical Befense, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Biochemical Befense by region & country, by Type, and by Application.
The Biochemical Befense market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biochemical Befense.
Market Segmentation
By Company
Emergent Biosolutions
Hytest
GSK
Sanofi
PharmAthene
Bavarian Nordic
SIGA Technologies
Arbutus Biopharma
DynPort Vaccine
Xoma Corporation
Ichor Medical Systems
Aeolus Pharmaceuticals
Achaogen
Elusys Therapeutics
Dynavax Technologies
Cleveland BioLabs
Soligenix
Alnylam Pharmaceuticals
Segment by Type:
Anthrax
Smallpox
Botulism
Radiation/Nuclear
Others
Segment by Application
National Defense
Military
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Biochemical Befense manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Biochemical Befense in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Biochemical Befense in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Biochemical Befense Product Introduction
1.2 Global Biochemical Befense Market Size Forecast
1.3 Biochemical Befense Market Trends & Drivers
1.3.1 Biochemical Befense Industry Trends
1.3.2 Biochemical Befense Market Drivers & Opportunity
1.3.3 Biochemical Befense Market Challenges
1.3.4 Biochemical Befense Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Biochemical Befense Players Revenue Ranking (2023)
2.2 Global Biochemical Befense Revenue by Company (2019-2024)
2.3 Key Companies Biochemical Befense Manufacturing Base Distribution and Headquarters
2.4 Key Companies Biochemical Befense Product Offered
2.5 Key Companies Time to Begin Mass Production of Biochemical Befense
2.6 Biochemical Befense Market Competitive Analysis
2.6.1 Biochemical Befense Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Biochemical Befense Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biochemical Befense as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Anthrax
3.1.2 Smallpox
3.1.3 Botulism
3.1.4 Radiation/Nuclear
3.1.5 Others
3.2 Global Biochemical Befense Sales Value by Type
3.2.1 Global Biochemical Befense Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Biochemical Befense Sales Value, by Type (2019-2030)
3.2.3 Global Biochemical Befense Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 National Defense
4.1.2 Military
4.1.3 Others
4.2 Global Biochemical Befense Sales Value by Application
4.2.1 Global Biochemical Befense Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Biochemical Befense Sales Value, by Application (2019-2030)
4.2.3 Global Biochemical Befense Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Biochemical Befense Sales Value by Region
5.1.1 Global Biochemical Befense Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Biochemical Befense Sales Value by Region (2019-2024)
5.1.3 Global Biochemical Befense Sales Value by Region (2025-2030)
5.1.4 Global Biochemical Befense Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Biochemical Befense Sales Value, 2019-2030
5.2.2 North America Biochemical Befense Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Biochemical Befense Sales Value, 2019-2030
5.3.2 Europe Biochemical Befense Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Biochemical Befense Sales Value, 2019-2030
5.4.2 Asia Pacific Biochemical Befense Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Biochemical Befense Sales Value, 2019-2030
5.5.2 South America Biochemical Befense Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Biochemical Befense Sales Value, 2019-2030
5.6.2 Middle East & Africa Biochemical Befense Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Biochemical Befense Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Biochemical Befense Sales Value
6.3 United States
6.3.1 United States Biochemical Befense Sales Value, 2019-2030
6.3.2 United States Biochemical Befense Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Biochemical Befense Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Biochemical Befense Sales Value, 2019-2030
6.4.2 Europe Biochemical Befense Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Biochemical Befense Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Biochemical Befense Sales Value, 2019-2030
6.5.2 China Biochemical Befense Sales Value by Type (%), 2023 VS 2030
6.5.3 China Biochemical Befense Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Biochemical Befense Sales Value, 2019-2030
6.6.2 Japan Biochemical Befense Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Biochemical Befense Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Biochemical Befense Sales Value, 2019-2030
6.7.2 South Korea Biochemical Befense Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Biochemical Befense Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Biochemical Befense Sales Value, 2019-2030
6.8.2 Southeast Asia Biochemical Befense Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Biochemical Befense Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Biochemical Befense Sales Value, 2019-2030
6.9.2 India Biochemical Befense Sales Value by Type (%), 2023 VS 2030
6.9.3 India Biochemical Befense Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Emergent Biosolutions
7.1.1 Emergent Biosolutions Profile
7.1.2 Emergent Biosolutions Main Business
7.1.3 Emergent Biosolutions Biochemical Befense Products, Services and Solutions
7.1.4 Emergent Biosolutions Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.1.5 Emergent Biosolutions Recent Developments
7.2 Hytest
7.2.1 Hytest Profile
7.2.2 Hytest Main Business
7.2.3 Hytest Biochemical Befense Products, Services and Solutions
7.2.4 Hytest Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.2.5 Hytest Recent Developments
7.3 GSK
7.3.1 GSK Profile
7.3.2 GSK Main Business
7.3.3 GSK Biochemical Befense Products, Services and Solutions
7.3.4 GSK Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.3.5 Sanofi Recent Developments
7.4 Sanofi
7.4.1 Sanofi Profile
7.4.2 Sanofi Main Business
7.4.3 Sanofi Biochemical Befense Products, Services and Solutions
7.4.4 Sanofi Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.4.5 Sanofi Recent Developments
7.5 PharmAthene
7.5.1 PharmAthene Profile
7.5.2 PharmAthene Main Business
7.5.3 PharmAthene Biochemical Befense Products, Services and Solutions
7.5.4 PharmAthene Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.5.5 PharmAthene Recent Developments
7.6 Bavarian Nordic
7.6.1 Bavarian Nordic Profile
7.6.2 Bavarian Nordic Main Business
7.6.3 Bavarian Nordic Biochemical Befense Products, Services and Solutions
7.6.4 Bavarian Nordic Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.6.5 Bavarian Nordic Recent Developments
7.7 SIGA Technologies
7.7.1 SIGA Technologies Profile
7.7.2 SIGA Technologies Main Business
7.7.3 SIGA Technologies Biochemical Befense Products, Services and Solutions
7.7.4 SIGA Technologies Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.7.5 SIGA Technologies Recent Developments
7.8 Arbutus Biopharma
7.8.1 Arbutus Biopharma Profile
7.8.2 Arbutus Biopharma Main Business
7.8.3 Arbutus Biopharma Biochemical Befense Products, Services and Solutions
7.8.4 Arbutus Biopharma Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.8.5 Arbutus Biopharma Recent Developments
7.9 DynPort Vaccine
7.9.1 DynPort Vaccine Profile
7.9.2 DynPort Vaccine Main Business
7.9.3 DynPort Vaccine Biochemical Befense Products, Services and Solutions
7.9.4 DynPort Vaccine Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.9.5 DynPort Vaccine Recent Developments
7.10 Xoma Corporation
7.10.1 Xoma Corporation Profile
7.10.2 Xoma Corporation Main Business
7.10.3 Xoma Corporation Biochemical Befense Products, Services and Solutions
7.10.4 Xoma Corporation Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.10.5 Xoma Corporation Recent Developments
7.11 Ichor Medical Systems
7.11.1 Ichor Medical Systems Profile
7.11.2 Ichor Medical Systems Main Business
7.11.3 Ichor Medical Systems Biochemical Befense Products, Services and Solutions
7.11.4 Ichor Medical Systems Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.11.5 Ichor Medical Systems Recent Developments
7.12 Aeolus Pharmaceuticals
7.12.1 Aeolus Pharmaceuticals Profile
7.12.2 Aeolus Pharmaceuticals Main Business
7.12.3 Aeolus Pharmaceuticals Biochemical Befense Products, Services and Solutions
7.12.4 Aeolus Pharmaceuticals Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.12.5 Aeolus Pharmaceuticals Recent Developments
7.13 Achaogen
7.13.1 Achaogen Profile
7.13.2 Achaogen Main Business
7.13.3 Achaogen Biochemical Befense Products, Services and Solutions
7.13.4 Achaogen Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.13.5 Achaogen Recent Developments
7.14 Elusys Therapeutics
7.14.1 Elusys Therapeutics Profile
7.14.2 Elusys Therapeutics Main Business
7.14.3 Elusys Therapeutics Biochemical Befense Products, Services and Solutions
7.14.4 Elusys Therapeutics Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.14.5 Elusys Therapeutics Recent Developments
7.15 Dynavax Technologies
7.15.1 Dynavax Technologies Profile
7.15.2 Dynavax Technologies Main Business
7.15.3 Dynavax Technologies Biochemical Befense Products, Services and Solutions
7.15.4 Dynavax Technologies Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.15.5 Dynavax Technologies Recent Developments
7.16 Cleveland BioLabs
7.16.1 Cleveland BioLabs Profile
7.16.2 Cleveland BioLabs Main Business
7.16.3 Cleveland BioLabs Biochemical Befense Products, Services and Solutions
7.16.4 Cleveland BioLabs Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.16.5 Cleveland BioLabs Recent Developments
7.17 Soligenix
7.17.1 Soligenix Profile
7.17.2 Soligenix Main Business
7.17.3 Soligenix Biochemical Befense Products, Services and Solutions
7.17.4 Soligenix Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.17.5 Soligenix Recent Developments
7.18 Alnylam Pharmaceuticals
7.18.1 Alnylam Pharmaceuticals Profile
7.18.2 Alnylam Pharmaceuticals Main Business
7.18.3 Alnylam Pharmaceuticals Biochemical Befense Products, Services and Solutions
7.18.4 Alnylam Pharmaceuticals Biochemical Befense Revenue (US$ Million) & (2019-2024)
7.18.5 Alnylam Pharmaceuticals Recent Developments
8 Industry Chain Analysis
8.1 Biochemical Befense Industrial Chain
8.2 Biochemical Befense Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Biochemical Befense Sales Model
8.5.2 Sales Channel
8.5.3 Biochemical Befense Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Emergent Biosolutions
Hytest
GSK
Sanofi
PharmAthene
Bavarian Nordic
SIGA Technologies
Arbutus Biopharma
DynPort Vaccine
Xoma Corporation
Ichor Medical Systems
Aeolus Pharmaceuticals
Achaogen
Elusys Therapeutics
Dynavax Technologies
Cleveland BioLabs
Soligenix
Alnylam Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂